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FOREWORD 
This study was initiated by Nycomed Pharmaceutical Norway. The company aimed at 
obtaining more information on Tachosil® which is a product that is used during surgery to 
stop bleeding or leakage of cerebrospinal fluid. Nycomed offered the project to master 
students who could use the study for a master thesis. Nycomed offered a student grant for the 
student who chose the project. 
The initial aim of the project thesis was to perform a full economic evaluation of Tachosil® 
in relation to a comparator, with patient data from Ullevål University Hospital. A meeting, 
which included my supervisor, my contact person from Nycomed, a neurosurgeon at Ullevål, 
the head of the Neurosurgical department at Ullevål and me, took place in October 2008. 
Together we decided that an economic evaluation of Tachosil® used in transsphenoidal 
surgery when removing pituitary tumours would be my topic for the thesis. Two additional 
meetings took place between November and January, at which we discussed the needed data 
material more in detail. Since I was not allowed access to patient records, an assistant 
resident physician was funded by Nycomed to go through the relevant patient records, a total 
of 82, and to find the information that would be relevant for my thesis. I received the data 
material in February, and unfortunately the data showed that Tachosil® only were used in 13 
operations, thus the distribution of patients between the groups were unequal. For that and 
other reasons, a full economic evaluation turned out to be impossible. 
I would like to acknowledge the following for providing valuable information: Zinajda Zolic 
and Nycomed, Aqeel A Chaudhry, Roger Josefsen and Glenn Knutsen. I would like to thank 
my supervisor Ivar Sønbø Kristiansen (MD PhD MPH, at The Institute of Health 
Management and Health Economics, University of Oslo) for sharing his valuable time and 
wisdom. Last but not least, my profound thanks go to my co-students; Katrine, Irina and 
Linn for all the laughs and coffee breaks we have shared during this master thesis period, 
and to my family for always believing in me. 
Cecilia Therese Olofsson  
Oslo, May 2009 
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ABBREVIATIONS AND ACRONYMS 
ACTH Adrenocorticotropic hormone 
ADP Adenosive diphosphate 
AVP Arginine vasopressin 
CBA Cost benefit analysis 
CCA Cost consequence analysis 
CEA Cost effectiveness analysis 
CMA Cost minimization analysis 
CSF Cerebrospinal fluid 
CUA Cost utility analysis 
DALY Disability adjusted life year 
DI Diabetes insipidus 
FSH Follicle stimulating hormone 
GH Growth hormone 
HrØoL Health related quality of life 
ICER Incremental cost-effectiveness ratio 
ICU Intensity care unit 
LH Lutenizing hormone 
NSB Net social benefit 
OR Odds ratio 
OT Oxytocin 
PRL Prolactin 
ØALY Quality adjusted life year 
RCT Randomized controlled trail 
RR Relative risk 
SG Standard gamble 
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SWC Standard ward care 
TSH Thyroid hormone 
TSS Transsphenoidal surgery 
TTO Time trade-off 
WTP Willingness to pay 
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ABSTRACT 
Background: Cerebrospinal fluid leakage and other complications followed from 
transsphenoidal surgery when removing pituitary tumours are rare but serious. Through 
studies and clinical trials, Tachosil® has proven to be an effective sealing agent, thus in 
preventing complications.   
Methods: Data of 82 patients that underwent transsphenoidal surgery for removing pituitary 
tumours in Ullevål University Hospital in the years 2006-2008 was collected. Statistical tests 
were performed to test the differences between the sealing techniques used during surgery in 
terms of patient characteristics, complication rates and length of stay. Costs expressed in 
2009 NOK of the sealing agents (Tachosil® and Neuro-Patch®), intensity care unit and 
standard ward care were identified.  
Results: The complication rate was 25% in the Neuro-Patch® group and 23% in the 
Tachosil® group (p=0.726). The mean ICU LOS in the Tachosil® group was 1.42 days and 
SWC LOS was 5.92 days, while the numbers were 1.93 and 7.93 in the Neuro-Patch® 
group. The differences between the two groups according to length of stay were not 
statistically significant. The mean ICU cost of a patient in the Neuro-Patch® group was 
NOK 52,200 and NOK 38,250 in the Tachosil® group (p=0.265). The mean SWC cost in the 
Neuro-Patch® group was NOK 38,080 and NOK 28,400 in the Tachosil® group (p=0.856). 
The mean cost of the sealing product was NOK 394 in the Neuro-Patch® group and NOK 
1,261 in the Tachosil® group (p<0.001). 
Conclusion: The results of this study do not provide any evidence that Tachosil® is superior 
in terms of complications or length of stay. 
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1. Introduction 
The history of neurosurgery goes back thousands of years (Mellergård, 1998). The oldest 
known surgical procedure is trepanation in which a hole was drilled into the skull to treat 
intracranial diseases. It is also believed that trepanation was used for mystical practices; to 
release tormented spirits. Evidence of trepanation is found in prehistoric human remains, 
suggesting that this procedure was used as early as during the later part of the Stone Age, 
around 6500 BC (Trepanation, 2009). Signs of structure healing on many of the skulls 
suggest that several “patients” actually survived the operations. Skulls with trepanation have 
been found in England, France and other European countries, as well as in Africa and South 
America (Mellergård, 1998). The earliest written documentation of neurosurgical practices 
are the so called “Edwin Smith Surgical Papyrus”, which is a copy of a text originally issued 
2500-3000 years BC. The text includes descriptions of the anatomy of the brain and 
procedures of head traumas. Around 400 BC, Hippocrates “the father of medicine” made 
elaborate observations of head traumatized patients and also indicated the use of trepanation. 
Some of his observations and ideas are still relevant today.  
 
Figure 1: Engraving of trepanation by Peter Treveris 
1525  
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The birth of the modern neurosurgery is often dated to the year 1879 when the Scottish 
William Macewen performed a historical intracranial operation of a left frontal menin
on a young woman with focal epileptic signs (Mellergård, 1998). The operation was 
successful and the woman lived for eight more years. During the following years he 
performed many successful operations, and he earned himself a well-deserved reputation. A
Englishman called Sir Victor Horsley is another well-known pioneer in neurosurgery, w
started his career as a surgeon at John Hopkins hospital in Baltimore after performing 
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hundreds of brain surgeries on monkeys. In 1887 he became the first physician to remove a 
spinal tumour, but he also became known for a number of technical innovations, including 
the haemostatic bone wax. While both Macewen and Horsley were general surgeons, H
Cushing from America consolidated neurosurgery as a speciality. The main part of his 
working life in the beginning of the 20
arvey 
in 
g teacher 
of neurosurgeons. His most famous discovery is the Cushing’s disease in 1932.  
s, 
d aseptics. 
ent bleeding and cerebrospinal fluid leakage and thus reduce the risks from 
neurosurgery. 
1.1 Haemostasis 
y 
ious 
fective mechanisms) or unwanted blood coagulations (hyperactive 
mechanisms).  
Haemostasis can be divided into three processes (Berkow et al, 1997): 
* Constriction of the injured blood vessel 
* Activation of the platelets 
* Activation of a number of blood clotting factors 
l 
t 
th century was spent at Peter Bent Brigham Hospital 
Boston and as a teaching professor at Harvard Medical School. He developed many of the 
basic surgical techniques for operating on the brain and became the worlds leadin
Neurosurgery entails many risks including bleeding, paralysis, cerebrospinal fluid leakage
brain damages, infections, various other complications and deaths. Two milestones in the 
improvement of outcomes from surgery were the introduction of anaesthesia an
Due to more recent technologies, interventions and a higher level of expertise, 
neurosurgeons are now able to perform more complex procedures at lower morbidity and 
mortality rates (Matula and Steiger, 2005). In the following, I will explore technologies that 
are used to prev
Haemostasis contains those mechanisms that contribute to halt bleeding after tissue injur
(Bjålie et al, 2003). It is necessary that these mechanisms work optimal to avoid ser
blood loss (inef
The blood platelets have a central role in the haemostasis (Bjålie et al, 2003). When a vesse
is injured, they form a plug that mechanically halts the bleeding, but they are also of grea
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importance during the other steps of the haemostasis. The blood vessels inner surface is 
normally smooth and unresponsive. When this inner surface is injured, it becomes reactive 
and the haemostatic mechanisms are triggered.  
d 
e 
 
o 
 released from the 
uninjured area, neutralizing the platelets activation (Bjålie et al, 2003). 
s, 
is 
s. 
 and results in dissolution of the clot. A vessel that has 
been clotted is now open again.  
                                             
When injured, the blood vessel immediately constricts so that the blood flow is reduced and 
the clotting can start. This constriction can last up to half an hour. The platelets are activate
and a number of reactions start as soon as the vessels wall breaks. A plasma protein called 
von Willebrand factor is produced by the cells of the vessels, working as glue to make the 
platelets stick to the injured area. The platelets bind to collagen1 in the exposed walls of th
blood vessel, releasing adenosine diphosphate (ADP)2 which causes the platelets to swell 
and aggregate (Hakim & Canelo, 2007). Further more, the platelets form thromboxane A2 3
which helps to make the platelets more adhesive. The clotting continues until the injury is 
plugged. To make sure that the clotting is limited to the injured area and doesn’t expand int
the uninjured parts of the blood vessel, an enzyme called prostacyclin is
The coagulation process involves sequential activation of a number of blood clotting factor
resulting in the formation of fibrin (Hakim & Canelo, 2007). First, when a blood vessel 
injured, prothrombin (factor II) is transformed into thrombin4. Thrombin then converts 
fibrinogen5 to fibrin, which is a protein consisting of inextricable threads, that ensnares 
blood cells for clotting in the injured area (Bjålie et al, 2003). When the tissue healing is 
present and there is no longer use for the clot, the clot will attract and stimulate the growth 
of fibroblasts and smooth muscle cells within the vessel wall, and begin the repair proces
This process is called fibrinolysis
 
1 Collagen is a fibrous structural protein that supports most tissues and gives cells structure from the outside, but it is also 
found inside certain cells.  
2 ADP is a nucleotide which is stored inside blood platelets. It is released when the platelets are activated. 
3 Thromboxane A2  is an eicosanoid which is a lipid. It is produced by platelets to stimulate activation of new platelets as 
well as increasing platelet aggregation.  
4 Prothrombin is found in an inactive state in the circulation system. When a vessel is injured, an inactive enzyme called 
factor X is transforming prothrombin into thrombin.  
5 Fibrinogen is a plasma glycoprotein that are synthesised by the liver.  
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Figure 2: The different steps of haemostasis, from injury to the dissolution of the clot 
1.2   Haemostasis in neurosurgery 
In neurosurgery, absolute haemostasis is essential (Hakim & Canelo, 2007). Perioperative 
complications involving bleeding may have serious consequences as blindness or paralysis. 
In a prothrombotic environment, the haemostatic process might become pathological and 
lead to thrombosis6. More seriously, neurosurgical patients are at risk of thromboembolism7, 
                                              
6 If the haemostatic process causes too much clotting inside a blood vessel, obstructing the blood flow, a thrombosis is 
formed.  
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which may lead to cerebral infarction. Patients with brain tumors may be at increased risk 
from use of procoagulants such as steroids, chemotherapeutic and hormonal agents. It is also 
believed that the tumors themselves are able to secrete procoagulant factors. Since there is a 
limitation of laboratory tests that can identify those in a prothrombotic state, it is important 
to be aware of, and to identify the risk factors that can lead to thromboembolism.   
1.3  Anatomy, physiology and function of the pituitary  
Hypothalamus is a region located below the lower part of the brain (Molina, 2006). It is 
crucial in both the autonomic nerve system and the endocrine system. The coordination of 
the endocrine system is done with the help of the pituitary, which is a pea-sized gland 
situated below the hypothalamus (fig 3).  
Figure 3: Location of the pituitary gland 
 
The pituitary is connected to the hypothalamus with the pituitary stalk and consists of an 
anterior (adenohypophysis) and a posterior lobe (fig 4). The posterior pituitary, which is the 
smallest one, consists of nerve fibres, glial cells and blood vessels, and is a part of the 
                                                                                                                                           
7 Thromboembolism is when a thrombus migrates from one part to another part (emboli), where it causes a blood blockage.  
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central nervous system. There are no hormone producing cells in the posterior pituitary, thus 
its hormones are produced in the hypothalamus. Instead it serves as a storage place for two 
peptide hormones called arginine vasopressin (AVP) and oxytocin (OT), produced in 
magnocellular neurosecretory cells of the hypothalamus. The releasing of these two 
hormones to the vessels and further transported into the body, depends on multiple reflexes 
and stimulation from neuroendocrine cells. AVP is most important for the function of the 
kidneys, since it regulates the body’s retention of water (Bjålie et al, 2003). But it is also 
involved in the haemostatic process, making the blood vessels constrict when injured. 
Oxytocin plays an important role in the female reproduction as it evokes constrictions in the 
uterus during birth, and it facilitates breastfeeding by pressing the milk through the canals 
when the nipples are stimulated.  
Figure 4:  Anatomy of the pituitary gland 
 
In contrast to the posterior pituitary, the anterior pituitary produces its hormones (Molina, 
2006). The pituitary stalk consists of a portal system (two capillary beds connected by small 
blood vessels) that links the anterior gland and the hypothalamus. The first capillary bed, 
located in the hypophyseal portal system of the pituitary stalk, receives transmitters from 
neurocells found in the hypothalamus. These neurocells are taken by blood vessels to the 
second capillary bed in the anterior pituitary where they bind to specific receptors of 
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hormone producing cells, then activated, released and taken by blood vessels to specific 
target cells. The anterior pituitary consists of many types of endocrine cells that produce 
different peptide hormones (Bjålie et al, 2003).The most important ones and their functions 
are summarized in Table 1. Several of these hormones stimulate, sometimes in addition to 
other functions, the production of other hormones. 
 
Table 1: The hormones of the anterior pituitary 
Hormones Function 
Adrenocorticotropic hormone Stimulates the secretion of steroid hormones 
(cortisol) in the adrenal cortex 
Beta-endorphin Inhibit pain 
Human growth hormone Stimulates growth 
Thyroid stimulating hormone Stimulates the secretion of thyroid hormones 
in the thyroid gland 
Follicle stimulating hormone Stimulates reproduction in the gonads 
Luteinizing hormone  Stimulates reproduction in the gonads 
Prolactin Stimulates milk production in the mammary 
gland 
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1.4 Cerebrospinal fluid 
The cerebrospinal fluid (CSF) is a colourless and clear fluid that occupies the surface of the 
central nervous system; more specifically it occupies the subarachnoid space which is the 
interval between the arachnoid mater and the pia mater8, and is contained within a system of 
fluid-filled cavities called ventricles (Bjålie et al, 2003; Cerebrospinal fluid, 2009). Compare 
to blood plasma, the concentration of glucose is smaller and there is much less protein. The 
ion composition is also different, made for optimal function of the neurocells. The CSF 
flushes through the nervous system, reproduced several times a day. The total volume of 
CSF in an adult human is about 150 ml, while 500 ml is produced every day. CSF is 
produced in the choroid plexus (the lateral ventricle), and further transported to the third 
ventricle through the interventricular foramen, which is also called the foramen of Monro. 
The fluid continues its way to the fourth ventricle, passing through the cerebral aqueduct 
(also called the Aqueduct of Sylvius), that serves as a link between the third and fourth 
ventricle. CSF then exits through the foramina of Luschka, of which there are two, and the 
foramen of Magendie, and is finally absorbed into the blood stream through structures called 
arachnoid villi, which are located along the superior sagittal sinus.   
  
Figure 5: Cerebrospinal fluid 
 
 
 
 
 
                                              
8 The pia mater, arachnoid mater and dura mater are the three meninges which is a system of membrane that envelops the 
central nervous system, mainly for protection.  
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1.4.1 Function of the cerebrospinal fluid 
Functions of the CSF include (Bjålie et al, 2003; Cerebrospinal fluid, 2009): 
 The CSF has the important role of protecting the brain from damage, as it works as a 
shock-absorber from blows against the head.  
 Since the brain is “floating” in CSF, the weight of the brain is greatly reduced, which 
reduces the pressure at the base of the brain. Also, there is little room in the skull for 
the brain to increase its volume (cerebral oedema). Then, to hinder pressure damages, 
CSF is drained away.  
 The CSF also protects the brain by functioning as an excretion of waste products, 
transporting damaging substances away from the brain and into the blood. 
 Hormones are transported, with the help of CSF, to areas of the brain where they may 
act.   
1.5 Pituitary tumours 
Pituitary tumours constitute about 8% to 15% of all surgically treated intracranial neoplasm 
(Helseth et al, 2003; Rumboldt, 2005). Most pituitary tumours are adenomas9 (Delellis et al, 
2004). If a pituitary tumour is relatively large (macroadenoma) it can put pressure on the rest 
of the normal pituitary and nearby structures causing vision loss, headaches, nausea, 
seizures, loss of normal anterior pituitary hormone production and more. There is great 
variation in size10, speed of growth, invasive growth and clinical features (Helseth et al, 
2003). Pituitary adenomas can be classified as functional or non-functional depending on if 
it is hormonally active. Approximately 75% to 80% of pituitary adenomas are hormonally 
active (Rumboldt, 2005).   
                                              
9 Adenomas are noncancerous, nonspreading growth. 
10 Microadenoma (<10 mm), and macroadenoma (>10 mm).  
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Figure 6: Pituitary tumour 
 
 
 
 
 
1.5.1 Growth hormone producing adenoma 
Growth hormone (GH) producing adenomas account for approximately 15-20 % of all 
pituitary adenomas (Helseth et al, 2003). They are clinically associated with either gigantism 
or acromegaly, depending on age of the patient at the start of the disease (Delellis et al, 
2004). Gigantism is usually occurring in younger patients, characterized with excessive 
growth and height above average. Signs of acromegaly are often missed for many years, 
since the disease has a slow progression. Acromegaly commonly affects adults in their 
thirties but often the diagnosis and treatment are delayed for 6 to 12 years. Typical signs of 
acromegaly are enlargement of hands, feet, nose, lips, tongue and ears, thick and sweaty 
skin, soft tissue swelling of internal organs ( kidney, weakening of muscularity of the heart), 
overgrowth of skeletal tissues, peripheral arthropathy (complication of inflammatory bowel 
disease), severe headache, loss of vision and more.  
1.5.2 Prolactin producing adenoma 
Prolactin (PRL) producing adenomas are usually very small and the mortality rate is low 
(Delellis et al, 2004). They account for approximately 25-30 % of all pituitary adenomas and 
are the most common pituitary adenoma in childhood and adolescence, more common 
among young females than young males (Helseth et al, 2003). They often appear later in life 
for men, thus often in the form of macroadenomas. PRL producing adenomas produce an 
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excess of the hormone prolactin, which can cause a decrease in normal levels of sex 
hormones11, affecting men and women differently.  
1.5.3 Thyroid producing adenoma 
The TSH producing adenomas are very rare, with an account of 1% of the pituitary 
adenomas (Delellis et al, 2004). There is often a delay in diagnosis, since the signs are few, 
which causes the adenomas to be invasive and aggressive (often macroadenomas). An 
overproduction of the thyroid hormones (thyroxine and triodothyronine) is called overactive 
thyroid disease or hyperthyroidism, and can cause an overstimulation of the metabolism. 
This may result in sudden weight loss (from diarrhoea), fast heartbeat, irritability and 
anxiety. 
1.5.4 Adrenocorticotropic producing adenoma  
The ACTH producing adenoma stimulates the adrenal gland to produce more cortisol 
(Delellis et al, 2004). This condition is called Cushing’s disease, the incidence is about 1-10 
new cases per million, and it represents 10-15 % of all pituitary adenomas (Helseth et al, 
2003). The ACTH producing adenomas usually appear between the ages of 30 and 40 years 
and are rare in childhood. Most ACTH producing adenomas are small microadenomas, but 
macroadenomas do appear. The signs and symptoms of Cushing’s disease may include 
weight gain in the abdomen and facial roundness, high blood pressure, steroid induced 
osteoporosis, thinning of the skin and stretch marks, insulin resistance (which may lead to 
diabetes mellitus), growth of fat on the back of the neck (a hump), easy bruising, polyuria, 
muscle weakness, depression and anxiety, and more.   
1.5.5 Gonadotropin producing adenoma 
Pituitary adenomas that produce an excess in follicle-stimulating hormone (FSH) and/or 
lutenizing hormone (LH), represents 3-5 % of all pituitary adenomas (Helseth et al, 2003). 
They usually do not cause symptoms, most of them are hormonally inactive, hence difficult 
                                              
11 Estrogen in women and testosterone in men. 
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to diagnose (Delellis et al, 2004). But visual disturbances, hypopituitarism and headaches do 
occur. They are especially difficult to diagnose in women, since the level of FSH increases 
after menopause. When diagnosed, the adenomas are often large invasive macroadenomas.  
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2. Transsphenoidal surgery  
Transsphenoidal surgery is the standard method, since the 1950s and 1960s, when removing 
pituitary tumours (Fatemi et el, 2008). The approach is through the sphenoid sinus which is 
the space behind the nose, from where the pituitary gland is accessible. Two variants of TSS 
is possible; the sublabial transseptal technique is to make an incision under the upper lip 
along the gum line and go through the base of the nose, and the transnasal technique is to go 
directly through the nose. The first TSS method being introduced was the sublabial 
transseptal method. However, in 1988, due to patient discomfort and mucosal traumas, the 
direct endonasal method was introduced, and is now the more common method.   
 
Figure 7: Transseptal versus 
transnasal technique 
 
 
 
 
 
 
 
 
 
TSS has evolved dramatically over the years, making it safer to remove both microadenomas 
and macroadenomas according to morbidity and mortality (Black et al, 1988). Due to 
improved endoscopes and adoption of advanced surgical techniques, the endoscopic 
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transnasal approach has been developed, providing a minimally invasive route and 
suggesting shorter hospital stay (Atkinson et el, 2008; Fatemi et al, 2008).  
Figure 8: Endoscopic transnasal approach 
 
2.1 Complications 
TSS is a reasonably safe procedure, suggesting a mortality rate of less than 1 % (Black et al, 
1987; Ciric et al, 1997; Tamašauskas et al, 2008). However, complications that may result in 
serious consequences do appear.  
2.1.1 Cerebrospinal fluid leakage 
Postoperative CSF leakage, also called CSF rhinorrhea12, is a serious and life-threatening 
complication (Tamašauskas et al, 2008). CSF leakage occurs when the meninges are 
damaged, usually as a consequence of head-trauma, surgical trauma or an invasive tumour 
(Han et al, 2008). If not treated in time, CSF leakage may lead to meningitis and, rarely, 
tension pneumocephalus and encephalopyosis, which are life threatening (Nishioka et al, 
2005; Han et al, 2008). A number of studies have been made on the frequency of 
postoperative CSF leakage when removing pituitary tumours and its rate varies from 1% to 
6% (Black et al, 1987; Cappabianca et al, 2002; Seiler et al, 2000; Tamašauskas et al, 2008; 
Han et al, 2008). The variation is suggested to be due to the experience of the surgeons, what 
                                              
12 Rhinorrhea, also known as”runny nose”, has the characteristics of an unusually significant amount of nasal discharge. 
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kind of technology that was used, the size and type of the tumour and the sealing technique 
of the sella turcica. According to several studies, intraoperative CSF leakages occur more 
often than postoperative, with a rate that varies from 14% to 19% (Cappabianca et al, 2002; 
Nishioka et al, 2005; Tamašauskas et al, 2008; Han et al, 2008).  
2.1.2 Diabetes insipidus 
Diabetes insipidus (DI) is a condition characterized by an extreme thirst and excessive 
urination, which is caused by a disturbance in the secretion of the AVP hormone. Causes for 
DI include damage to the hypothalamus, head trauma, tumours and cranial surgery. 
Mortality is rare but other consequences such as severe hydration may follow if not treated 
in time. Not all cases of DI are permanent and can be treated with drugs. Tamašauskas noted 
7 % transitory DI following TSS when removing pituitary tumours, compare to 2.8 % non-
transitory (Tamašauskas et al, 2008). These rates seem to vary when comparing to other 
studies, but are consistent in that transitory DI is more common than non-transitory DI 
(Black et al, 1987; Ciric et al, 1997).  
2.1.3 Meningitis 
Meningitis is a serious condition that is caused by an inflammation of the meninges, usually 
caused by infection with microorganisms. There are different types of meningitis as well as 
different causes. During TSS, bacteria’s from the nasal cavity may be entering the meninges 
area, and in some cases cause meningitis. Meningitis may also follow from CSF rhinorrhea. 
Meningitis following TSS for pituitary tumours is rare, studies suggest en incidence rate that 
varies from 0.4% to 2% (Black et al, 1987; Ciric et al, 1997; Tamašauskas et al, 2008). The 
first symptoms are usually severe headaches, fever, vomiting, neck stiffness, sensitivity to 
bright light and confusion. If not treated in time, meningitis may have serious consequences 
such as deafness, epilepsy, cognitive deficits, and even death. 
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3. Sealing techniques 
Since the beginning of modern neurosurgery surgeons have been confronted with intra-and 
postoperative complications such as bleeding, CSF-leakages and infections (Matula and 
Steiger, 2005). Especially sealing of the dura mater has been hard to achieve.  
There are various techniques for repairing the sella turcica when undergone TSS for pituitary 
tumours. Autologous tissues such as fat, muscle graft and fascial has in the last years been 
replaced by a variation of synthetic materials such as fibrin glue and different types of 
collagen sponges (Cappabianca et al, 2004; Kelly et al, 2001; Seda et al, 2006). 
3.1 Tachosil®   
Tachosil® (manufactured by Nycomed) is a ready-to-use fixed combination of a collagen 
sponge, produced from horse tendons, coated with a layer of the coagulation factors; human 
fibrinogen and human thrombin (Tachosil® product monograph, 2006). When applied to a 
surface of blood or other fluid, Tachosil® achieves haemostasis and sealing within 3-5 
minutes. The patch can be cut in suitable pieces to fit small wound areas. Once Tachosil® 
comes in contact with liquid it becomes pliable and easy to apply, making it useful for hard-
to-reach wounds. The patch comes in sterile packages, requires no preparations, and comes 
in three different sizes.  
 
Figure 9: Three different sizes 
of Tachosil®. The yellow
(riboflavin) colour shows the
active side of the patch, which 
is coated with human
coagulation factors 
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Figure 10: The mechanisms of Tachosil®. When the yellow side is applied on the wound 
(1), the coagulation factors are released (2) and fibrin is generated (3). The patch 
structure folds in, resulting in an air- and liquid- tight sealing of the wound (4). 
Tachosil®  is absorbed by the body within 12 weeks of the procedure  
Tachosil® is a further development of TachoComb® and TachoComb® H that was 
introduced to the market in the early 1990s (Matula & Steiger, 2005). Tachosil® differs 
from its predecessors in that it is free from bovine components, thus the risk of transmission 
of prions or other germs from cattle to patient is eliminated.  
3.1.1 Earlier studies of Tachosil® 
My search in the PubMed database for Tachosil® in randomized controlled trials resulted in 
four articles. S. Siemer et al conducted a randomized prospective study of the efficacy and 
safety of Tachosil® as a haemostatic treatment versus standard suturing in kidney tumour 
resection. A total of 185 patients were included in the study. The time to haemostasis was 
significantly shorter with Tachosil® than standard suturing (mean: 5.3 min versus 9.5 min 
[p<0.0001]) (Siemer et al, 2007). In the Tachosil® group, haemostasis was obtained within 
10 min in 92% of the patients, compared to 67% in the standard treatment group (p<0.0001). 
There were no statistically significant differences in terms of safety and other secondary 
objectives, although surgeons considered Tachosil® to be more convenient to prepare and to 
apply.  
An open randomized prospective trial to assess the effectiveness of Tachosil® versus argon 
beamer as a haemostatic agent during liver resection was reported in 2004 by A. Frilling et 
al. A number of 121 patients requiring secondary haemostasis during planned liver resection 
were included in the study. The study showed Tachosil® to be superior over argon beamer 
with regard to time to haemostasis (mean 3.9 min, median 3.0, range 3-20 min versus mean 
6.3 min, median 4.0, range 3-39 min [p=0.0007]) (Frilling et al, 2004). There was a 
significantly shorter drainage period seen in the argon beamer group (mean: 5.7 days versus 
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8.2 days [p=0.005]). However, Frilling suggests that this could be due to the physicians 
being more cautious in removing drain from test patients (Tachosil®) than from patients 
who received standard treatment (argon beamer). There were no statistically significant 
differences in terms of adverse events.  
Tachosil® has become an increasingly used approach during lung surgery. U. Anegg et al 
conducted in 2007 a randomized trial, including 152 patients, to investigate the efficiency of 
Tachosil® (TS group) versus standard therapy (ST group) for treating air leaks after lung 
resection. The 152 patients were randomized; 75 to the TS group and 77 to the ST group. 
The mean time to chest drain removal and mean time to hospital discharge was also 
investigated. A t-test for independent samples was performed, and a p-value <0.05 was 
considered to be significant. The mean intraoperatively post-treatment air leakage on 
postoperative days 1 and 2 was significantly lower in the Tachosil® group compared to the 
standard treatment group (153.32 ml/min, range 10-450 ml/min versus 251.04 ml/min, range 
15-970 ml/min [p=0.009]) (Anegg et al, 2007). There was also a significant difference in the 
mean time to chest drain removal (5.1 days versus 6.3 days [p=0.022]) and time to hospital 
discharge (6.2 days versus 7.7 days [p=0.01]), both in the favour of the Tachosil® group. No 
significant differences in adverse events were observed. In 2008, Anegg et al presented a 
follow-up paper where the objective was to compare the costs of the materials and the costs 
of hospitalization between the two groups. They found an overall cost reduction of €98 in 
favour of the Tachosil® group (Anegg et al, 2008). Because the confidence intervals for the 
costs were wide, it could not be concluded that Tachosil® was superior over the standard 
treatment group.  
Another prospective randomized trial on alveolar air leaks after pulmonary resection was 
conducted by A. Droghetti et al in 2008. One group of 20 patients received a combination of 
electrocautery treatment and Tachosil® (ES), and the other group of 20 patients had a 
routine surgical procedure with staplers (ST). The main goal was to compare the percentage 
of patients in the two groups who were free of air leaks throughout hospitalization. The 
incidence of air leaks in the first 48 hours in the ES group was 50% compare to 95% in the 
ST group (p=0.0001) (Droghetti et al, 2008). The duration of air leaks was 1.7 days in the 
ES group versus 4.5 days in the ST group (p=0.003). The procedure costs, timing of chest 
tube removal, complications and the length of hospitalization were compared as secondary 
objectives. Procedure costs were lower in the ES group (€425) compare to the ST group 
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(€630.5) (p=0.0001). There were no statistical significant differences between the groups in 
terms of time to chest tube removal, hospitalization and complications; however, there were 
indications of differences. Studies with larger sample sizes would be necessary to investigate 
these issues.  
One study of the effectiveness of Tachosil® as a sealing agent after surgical removal of 
pituitary tumours was found in the PubMed database. The Department of Neurosurgery of 
Kaunas University of Medicine started in 1995 a prospective study of patients undergoing 
TSS for removing pituitary tumours (Tamašauskas et al, 2008). By 2005, 313 patients 
underwent 356 operations. The main objective of the study was to evaluate the frequency 
and the causes of intra- and postoperative CSF leaks and to discuss methods for closing the 
sella. The frequencies of other complications (meningitis, diabetes insipidus, and more) were 
also evaluated. 58 cases of intraoperative CSF leaks were observed, and for these cases; two 
different techniques for closing the sella were used. The first one was to pack the sella and 
the sphenoid sinus with autologous fat13 and to restore the defect of the sella turcica with 
autologous bone, and the second one was to place Surgicel® on the defect of the sella 
membrane and a Tachosil® plate on top of it, then to pack the sella with autologous fat and 
cover the dura mater defect with Surgicel® and Tachosil®. Of the 29 patients in the first 
group, 12 experienced postoperative complications (41%), compare to 4 patients out of 29 in 
the other group (14%) (p=0.02). From this result, Tamašauskas concluded that the multilayer 
technique of using Surgicel® and Tachosil® was a reliable technique.   
Table 2: Postoperative complications (Tamašauskas et al, 2008) 
Postoperative complications Method 1 Method 2 
Postoperative CSF leak 
Hypopituitarism 
Sphenoidal sinusitis 
Transitory diabetes insipidus 
Permanent diabetes insipidus 
Paresis n. oculomotorius 
Intraventricular hemorrhage 
3 
1 
2 
3 
2 
1 
0 
0 
0 
0 
2 
1 
0 
1 
Total 12 (41.4 %) 4 (13.8 %) 
 
                                              
13 Autologous fat refers to fat that are reimplanted in the same individual that it came from.  
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Several studies have been made evaluating the effectiveness of TachoComb® in 
neurosurgery as a dural repair agent. In 2002, M Reddy et al performed a retrospective 
review of 288 patients undergoing neurosurgery (operations on the brain, as well as spinal 
operations) where primary closure was not possible, using TachoComb® as a dural 
substitution. There were no cases of postoperative wound infections detected within a 32-
months follow-up (Reddy et al, 2002). Postoperative CSF leaks were developed in five 
cases, rebleeding in one case, and subcutaneous CSF accumulation without leak in four 
cases. Reddy et al concluded TachoComb® to be an adequate alternative for dural 
substitution. Reddy et al presented in 2003 another retrospective study, this time using 
TachoComb® after primarily closure of the dura mater with sutures. Twelve patients out of 
421 developed a subcutaneous CSF collection, thus TachoComb® was found to be an 
adequate agent for dural closure (Reddy et al, 2003).  
3.2 Neuro-Patch® 
Neuro-Patch® (manufactured by B. Braun Melsungen AG) is a type of microporous fabric 
made from a highly purified polyesterurethane, and is used as a dura mater substitution in 
neurosurgery (Neuro-Patch® product monograph, undated). To produce Neuro-Patch®, a 
dissolved polyesterurethane polymer is sprayed through electronically controlled specialised 
jets which cause a formation of uniform fibres. These fibres are captured at defined angles 
by a rotating cylinder, producing the basis of the fleecelike structure of Neuro-Patch®. In 
neurosurgery, the patch is fixed with non-absorbable suture material, and secured with fibrin 
glue. Neuro-Patch® can be cut into suitable pieces and comes in seven different sizes.  
Neuro-Patch®, and the polyesterurethane used for production of Neuro-Patch®, has been 
tested in several animal experimental investigations, showing tissue tolerability and 
biostability. The patch has also been used as a dura mater substitute in clinical trials on 
humans, and has allegedly showed positive results when preventing CSF-leaks (Neuro-
Patch® product monograph, undated).   
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4. Economic evaluation 
Because of scarce resources available to spend, it is impossible to meet all demands (Brazier 
et al, 2007). This is true for most aspects of life, and health care is no exception. Economic 
evaluations are tools that are available for decision makers to help them make “right” 
decisions about how these resources should be spent. This aim is reached by identifying, 
measuring, valuing and comparing the costs and consequences of health care interventions 
(Drummond et al, 2005). There are three different approaches of full economic evaluation: 
Cost-Benefit Analysis (CBA), Cost-Effectiveness Analysis (CEA) and Cost-Utility Analysis 
(CUA). They all use monetary units when measuring and identifying costs, but differ in the 
way the consequences are being valued. A fourth approach called Cost-Consequence 
Analysis (CCA) is sometimes included.  
4.1 Cost-Effectiveness Analysis 
This approach measures health benefit in a non-monetary unit, for example life-year gained 
or the number of diabetes II prevented, and the result will be presented as cost per health 
benefit. Since CEA does not use generic measure of outcome, it is difficult to compare 
across studies. CEA is most often used in situations where a decision maker is operating 
with a given budget, and therefore has limited range of options (Drummond et al, 2005). The 
decision maker seeks to maximize the benefits within this given budget, by ranking the 
treatments or interventions according to their cost-effectiveness. The incremental cost-
effectiveness ratio (ICER) is a term used in economic evaluation to compare the difference 
in cost and benefits of two or more treatments or interventions.  
Equation 1: 
   ∆C ⁄ ∆E  = ICER   
 
Figure 11 represents two different interventions (A and O) and the difference in effect 
(horizontal axis) and cost (vertical axis). When point A is in quadrant II, where the 
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intervention (A) is more effective and less costly than O, it will be the dominant alternative 
and is clearly preferred. In quadrant IV, where the intervention is less effective and more 
costly, alternative O is preferred. In quadrants II and III the choice will depend on the 
maximum cost-effectiveness ratio one is willing to accept, often referred as the cost-
effectiveness threshold  or the willingness to pay (WTP) (Drummond et al, 2005).  
Figure 11: The cost-effectiveness plane 
 
When the outcomes of alternative health care interventions or treatments are identical, a 
CEA is equivalent to a Cost-Minimization Analysis (CMA). However, because of a usual 
uncertainty around the measure of outcome, a full probabilistic CEA is often more preferred 
(Brazier et al, 2007). 
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4.2 Cost-Utility Analysis 
In CUA, the incremental cost of a programme from a particular viewpoint is compared to 
the incremental health improvement attributable to the programme, where the health 
improvement is measured in quality-adjusted life-years (QALYs) gained, or possibly some 
variant, like disability-adjusted life-years (DALYs) gained. The results are expressed as a 
cost per QALY gained (Drummond et al, 2005). 
CUA can be seen as a form of CEA in terms of comparing interventions as their cost per 
units of effect (Drummond et al, 2005). The unit of effect, a year in full health (QALY), is 
measured on an interval scale which combines length of life with health-related quality of 
life (HRQoL) (Brazier et al, 2007). This means that the QALY capture both morbidity and 
mortality, thus is a generic measure that is able to compare across studies. The following 
equation, where H = HRQoL and T = expected lifetime, shows how to calculate QALY. 
   Equation 2: 
    QALY = H * T 
The number of QALY is calculated by multiplying a person’s life expectancy by the value of 
the health-related quality of life measured on a scale between zero and one, where zero is 
dead and one is full health (Brazier et al, 2007). Some health states may be considered worse 
than death and will then have negative scores. Since the outcomes of any given intervention 
are uncertain, the probability must be taken into account to calculate the expected value of 
each possible outcome. Any QALY benefit has the same effect on preferences. This means 
that an increase of health from 0.1 to 0.3 is the same as an increase of health from 0.7 to 0.9, 
ten years of health at 0.5 is the same as five years of full health (which is one) and two 
people benefiting by five QALY each is the same as one person benefiting by ten QALY. 
There are various methods for measuring individual preferences, including visual analogue 
scale (VAS), standard gamble (SG) and time trade-off (Drummond et al, 2005).  
Similar to CEA, the CUA approach is useful under budget constraints or thresholds, when 
decisions between interventions must be made. But importantly, when using the CUA 
approach, comparisons can be made between interventions with more than one kind of 
health outcome, including side effects, so it is a useful tool for decision-makers when and 
how to prioritize resources. It also have the advantages that interventions of the same 
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condition with different health outcomes can be compared against each other and 
interventions for different kinds of health problems with different health outcomes can also 
be compared.  
4.3 Cost-Benefit Analysis 
When using the CBA approach, both the cost and the benefits are measured in monetary 
units. This gives CBA the advantage, in contrast to CUA and CEA, of being a useful tool in, 
and across, all sectors of the economy. In short, an intervention is worthwhile if the benefits 
exceed the costs, meaning that the Net Social Benefit (NSB)>0 (Drummond et al, 2005). 
When policy makers are limited by a fixed budget, it is useful for them to know the NSB of 
a project to be able to rank the options and choose the “right” one.  
One challenge is how to value, or translate, health benefits into monetary terms. There are 
three general, but different, approaches when valuing health outcomes (Drummond et al, 
2005): 
 The human capital approach (present value of future earnings) 
 The revealed preferences approach (individual preferences regarding the value of 
increased health risk, also called wage-risk approach) 
 The contingent valuation approach (stated preferences of WTP) 
4.4 Cost-Consequence Analysis 
There are arguments of whether CBA, CEA, and CUA are able to capture all relevant and 
legitimate concerns or not, for example some concerns that are related to equity and 
efficiency (Drummond et al, 2005). In a CCA, all the relevant concerns and factors are 
presented in the form of a table, and do not have a single number to enable a unique and 
complete ranking of different treatment options. It is then left to the decision maker to decide 
which treatment that is preferred. The problems of CCA is that it will not be clear how 
decisions actual would or should be made, since they will not be based on explicit values.  
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5. Epidemiological concepts and study design 
Epidemiology is, in short, a science that primarily studies the patterns of disease in a 
population, and that seek to understand the causes, effects and burdens of disease (Bhopal, 
2002). This knowledge is essential in healthcare policy, when planning to prevent and 
control disease, and to improve health. Epidemiology focuses foremost on the patterns of a 
population rather than on the single individual, since disease is influenced by the interaction 
and composition of individuals, and because epidemiology is highly dependable on 
demographic population data.  
Measurement is a central feature of epidemiology (Rothman, 2002). There are several 
methods and measurements to apply when measuring the occurrence of disease and when 
studying the causes of disease. Risk or incidence proportion could be defined as the 
probability of an individual to develop a disease in a defined population and during a defined 
time period. If A represents the number of people developing disease during a time period, 
and N represents the total number of people during the same time period, the proportion A / 
N represents the average risk of disease in the population during that time period.  
Risk (incidence proportion) = A / N 
When measuring disease frequency in epidemiology, the incidence rate and the prevalence 
rate are the two principal measures. The incidence rate could be defined as the frequency of 
new occurrences of a disease in a population at risk of the disease during a period of time. 
The difference between incidence proportion and incidence rate is that the incidence rate is 
expressed as the number of new cases per unit of person-time at risk, for example per year, 
while incidence proportion only use time. Using the incidence rate handles situations where 
the amount of observation time differs between people, or when the population at risk varies 
with time. 
Incidence rate = A / Sum of time periods 
The prevalence rate could be defined as the number of occurrences of a disease in a 
population at risk of the disease either at a given point in time (point prevalence) or over a 
time period (period prevalence, lifetime prevalence).  In short, the incidence rate focuses on 
the number of new occurrences while the prevalence rate focuses on all occurrences. 
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Figure 12: Incidence versus prevalence 
 
Epidemiological studies often seek to make comparisons between populations groups, 
different places and over time (Bhopal, 2002). To see how the risk of a disease varies 
between populations, the relative risk (RR), which is the ratio of two incidence rates, can be 
calculated. More importantly, the RR is a useful tool when calculating the size of an effect of 
a risk factor on a disease. This is done by comparing the incidence rates between two 
population groups, one exposed to a specific risk factor, the other not. Although the formula 
for RR is simple, the interpretation is not. The two population groups could differ in many 
ways, not just by being exposed to a specific risk factor, which could affect the incidence 
rates for the disease. RR can never be calculated from a case-control study which do not 
provide data on incidence, but the odds ratio (OR) can be calculated and give a measure of 
the relative odds for being exposed to a causal factor in diseased and non-diseased 
individuals. The odds are the chances in favour of one event in relation to another event. In 
epidemiology, the odds are the chances of being exposed to a risk factor (or being sick) as 
opposed to not being exposed to a risk factor (or being sick). The OR is one set of odds 
divided by another. If there is no association the OR will be one. Table 3 shows how to 
understand and calculate RR and OR. 
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Risk factor Diseased Not diseased Total 
Present A B A + B 
Not present C D C + D 
Total A + C B + D A + B + C + D 
 
The incidence in the group with the risk factor = A / A + B 
The incidence in the group without the risk factor = C / C + D 
RR = (A / A + B) / (C / C + D) 
OR = (A x D) / (C x B) 
Table 3: Incidence rate, relative risk and odds ratio (Bhopal, 2002) 
5.1 Biases and confounding 
In epidemiology, a bias arises when errors affect comparison groups unequally, leading to 
false understanding about the patterns of disease (Bhopal, 2002). Biases are often 
categorized into three groups; selection bias, information bias and confounding. Bhopal 
agues that this list is incomplete, and that hypothesis bias, intervention bias, interpretation 
bias, and publication bias also should be included.  
A biased hypothesis implies that a research question could affect one group more than the 
other, by not being neutrally stated. To pose the research question “Are men healthier than 
women?” is to be considered as a biased question. The way the question is stated reveals a 
presumption that this is the case, and could affect the study at a later state. The values and 
beliefs of the researcher should be revealed as rarely as possible, also for ethical reasons.  
A selection bias is due to the method of collecting data, often the collection of samples. For 
convenience reasons, some population groups, for example volunteers, tend to be more used 
in studies than others. The problem is that volunteers may be different in their behaviour, 
attitudes, status, and more compared with those who do not volunteer, so only including 
volunteers in a study will not give a true picture. Some population groups are excluded from 
major studies for not speaking the language, being less accessible, or for belonging to a 
minority group. Also, some population groups tend to be excluded as a result from the 
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chosen source of a study population, for example the usage of the register of licensed 
drivers. A non-response bias is a form of selection bias where the subject chosen for a study 
do not participate. Since it is likely that these non-responders differ in characteristics from 
those that do respond, ignoring that could lead to selection biases, especially if the number 
of non-responders differs greatly in two groups being compared.  
Confounding means that there is an error in the assessment of the association between a 
disease and a potential causal factor, meaning that there could be other variables (that is not 
considered in the study) causing the effect, rather than the postulated causal factor. 
Confounding often appears when comparing population groups that differ in characteristics. 
Randomization is one way to address the problem of confounding but it is no guarantee for 
avoiding it completely, especially in small and subgroup studies.  
 
Figure 13: The relationship 
between the disease (dependent 
variable), the associated 
apparent risk (independent 
variable), and the confounding 
factor  
Confounding
 
 
The figure shows that the confounding factor, which is the true causal factor, is associated 
both with the apparent risk factor and the disease. One example could be a study that shows 
that alcohol (independent variable) is associated with lung cancer (dependent variable). By 
now we know that smoking is the main cause for lung cancer, but also that it is related to 
alcohol (people that drink alcohol tend to smoke more than people who don’t drink alcohol). 
Smoking will then be the confounding factor, which is the true cause for lung cancer. 
An information bias is a bias in measurement of exposure or outcome, and is a common 
problem. It can be caused by biological variations, inaccurate observations and tests, 
machine imprecision, variation in data collection, and more. Measurement errors could lead 
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to misclassification bias where a person is put in the wrong group. This is common in 
screening tests, where measurement errors are measured by the concepts of sensitivity and 
specificity.  
The biases in interpretation- and publication of data are mostly related to the behaviour, 
interests and expertise of the researcher.   
5.2 Study design 
Epidemiological studies vary in its designs but share the same key purposes, which are to 
understand disease causation and burden of disease (Bhopal, 2002). Five classifications 
distinguish between descriptive and analytic studies, retrospective and prospective studies, 
observational and experimental studies, presence and absence of disease in the beginning of 
the study, and studies with a control group or not. There is great variation in how the 
different epidemiological study designs fit these classifications.  
A cross-sectional study is an observational study that provides a “snapshot” of the patterns 
of diseases and risk factors in a representative part of the population at a point in time. The 
main research purposes are to measure prevalence of diseases, though also to seek 
associations between diseases and risk factors and to test or generate hypotheses. A cross-
sectional study can be used to measure change in disease patterns and to evaluate 
interventions, by performing repeated studies in different time periods (repeated cross-
sectional or panel design). Data about the past medical history of a general (well) population 
can be collected and show a wide spectre of diseases, but will then only give an indirect 
insight of the natural history. People that are institutionalized from severe diseases may be 
missed because they might not be on the sample list.  
A case-control study is an observational study where one group of people with a disease are 
compared to another group of people without that disease (control group). The control group 
yields information about the expected risk factor profile in the population from which the 
case group is drawn. To be as representative as possible, the set of cases would ideally be 
incident cases, usually obtained from population registers and new cases identified in cohort 
studies. The control group should not have the same pattern of exposure to the cause, but 
they should be alike in the matter of other characteristics. The controls may be chosen to 
 38 
match each case, for example in age and sex, to reduce the risk of confounding. Since some 
diseases develop over years, it is necessary to collect information on causal exposure from 
the past. The associations between a disease and a causal risk factor are measured by the 
difference in odds of being exposed to the potential causal factor in the case and the control 
group. The main research purpose is then to test whether the odd ratio is different from one.  
A cohort study is a longitudinal study in which data are collected at two or more points in 
time from the same individuals, who has something in common, for example, smoking 
habits. The purpose is to investigate whether one or more exposures are related to later 
disease. A cohort study is then a prospective study that seeks to measure the incidence rate 
of a disease. An example; Two groups are identified in the base population, those who 
smoke and those who don’t. These groups are tracked over time to identify the number of 
new cases of lung cancer in both groups, and to compare its incidence rates and find the 
relative risk. The result will provide us information about the impact smoking has on lung 
cancer, although the quality of the result will highly depend on the size and composition of 
the group, as well as the timeframe and quality of data. A cohort study can also be 
retrospective, where the exposure status is assembled from the past and the outcomes are 
explored in the present.  
A randomized clinical trial is an experimental study where individuals are exposed or not 
exposed to an intervention based on a random process such that other causal factors are 
equally distributed among the two groups. The design is similar to that in a cohort study, 
with one significant difference, that the exposure status of the individuals has been 
deliberately chosen by the investigator. The purpose of the clinical trial is to see how the 
intervention or change in other exposure will influence the incidence of disease or other 
features of the natural history of disease. First a suitable population is defined, and then 
divided into one intervention group and one control group. To avoid confounding, the 
individuals should be randomly chosen for one group or the other. There are different 
variants of randomized clinical trails (RCT) including blinding and use of placebos. A 
placebo treatment for the control group has no effect on the disease itself, only a possible 
psychologically impact. To avoid bias, the information about who is in the intervention 
group or the placebo group is kept a secret from the participants, so called blinding. If the 
health carers also do no know, it is called double blinding, and triple blinding when the field 
investigator is added.  
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6. Research question and hypotheses 
On the basis of the reviews of pituitary tumours, treatment, complications and different 
sealing techniques, I conclude that although pituitary tumours are rare and TSS is a 
reasonable safe procedure, one can not disregard that serious complications do occur and 
that the choice of sealing technique may affect the incidence of these complications as well 
as the outcome of those. The primary objective of this master thesis was to investigate the 
effectiveness of Tachosil® when used in TSS on pituitary tumours, by using Neuro-Patch® 
as a comparator. Earlier studies suggest Tachosil® (and TachoComb®) to be an effective 
sealing agent for this type of surgery (Czepko & Kwinta, 2006; Tamašauskas et al, 2008), 
and based on those study results I state the following hypotheses:   
1) CSF-leaks 
H0: Tachosil® and Neuro-Patch® are equally effective in preventing CSF-leaks followed 
from TSS when removing pituitary tumours. 
HA: Tachosil® is more effective than Neuro-Patch® in preventing CSF-leaks followed from 
TSS when removing pituitary tumours. 
2) Meningitis 
H0: Tachosil® and Neuro-Patch® are equally effective in preventing meningitis followed 
from TSS when removing pituitary tumours. 
HA: Tachosil® is more effective than Neuro-Patch® in preventing meningitis followed from 
TSS when removing pituitary tumours. 
3) Diabetes insipidus 
H0: Tachosil® and Neuro-Patch® are equally effective in preventing diabetes insipidus 
followed from TSS when removing pituitary tumours. 
HA: Tachosil® is more effective than Neuro-Patch® in preventing diabetes insipidus 
followed from TSS when removing pituitary tumours. 
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4) Bleeding 
H0: Tachosil® and Neuro-Patch® are equally effective in preventing bleeding followed 
from TSS when removing pituitary tumours. 
HA: Tachosil® is more effective than Neuro-Patch® in preventing bleeding followed from 
TSS when removing pituitary tumours. 
5) Fatality rate 
H0: Tachosil® and Neuro-Patch® are equally effective in preventing fatalities followed 
from TSS when removing pituitary tumours.  
HA: Tachosil® is more effective than Neuro-Patch® in preventing fatalities followed from 
TSS when removing pituitary tumours. 
6) Resource use: Length of stay at the intensity care unit 
H0: The Tachosil® group and the Neuro-Patch® group have equal length of stay at the 
intensity care unit.  
HA: The Tachosil® group have shorter length of stay at the intensity care unit than the 
Neuro-Patch® group.  
7) Resource use: Length of standard ward care  
H0: The Tachosil® group and the Neuro-Patch® group have equal length of stay at the 
standard ward care unit.  
HA: The Tachosil® group have shorter length of stay at the standard ward care unit than the 
Neuro-Patch® group.  
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7. Methods 
7.1 Literature search 
To get an insight into the relevant literature needed when conducting this study, I performed 
a literature search, focusing on articles published in the PubMed database. I used a 
combination of the three following keywords: Pituitary tumour; Transsphenoidal surgery; 
Cerebrospinal fluid rhinorrhea. These keywords were combined with additional terms such 
as: Endoscopic surgery; Sella turcica repair; Tachosil®; Prevalence; Incidence; etc. Also, 
relevant references mentioned in the identified articles were used. 
Additionally, Nycomed provided me with articles and studies of Tachosil® used in several 
areas and purposes, and I have included these in my study. B. Braun Melsungen AG 
provided me with information on Neuro-Patch®. 
7.2 Data collection from Ullevål University Hospital 
Data for 82 patients who had undergone TSS for removing pituitary tumours at Ullevål 
University Hospital in the years of 2006-2008 were collected by an assistant resident during 
the second week of February in 2009 (Appendix 1). All neurosurgical operations at Ullevål 
are registered manually in operation protocols, and these protocols were searched through 
twice to identify the operations with operation code for TSS on pituitary tumours. When 
those patients were identified, their medical records were found in the Pasdoc-system, which 
is the EPJ used at Ullevål.  
The size in millimetre of the tumour was measured on the MR-images taken prior to surgery. 
When a tumour was smaller than 10 mm it was classified as a microadenoma and otherwise 
a macroadenoma. When patients experienced vision affection, an examination was usually 
done by an ophthalmologist prior to surgery. In case of an acute surgery, the neurosurgeon 
performed the vision test. When there was suspicion of meningitis (fever, neck stiffness, 
sensitivity to bright light etc), a sample of the CSF was tested for glucose. If the 
concentration of glucose was lower than half of the concentration in the blood, it was taken 
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as a sign of meningitis. It may take some time before the test is analysed, so if there was 
strong suspicion of meningitis, antibiotic therapy was immediately given to the patient. The 
expert judgement of the physician was the basis for deciding when CSF-leaks and bleeding 
was present. All operations between 2006 and 2008 were performed by the same surgeon. 
The follow-up time of the number of deaths was within one month after the patient was 
discharged from the hospital.   
7.3 Costs 
All costs were measured in 2009 Norwegian Kroner (NOK), and VAT was excluded (Table 
4). The costs that were identified measured and valued was the product costs of Tachosil® 
and Neuro-Patch®, and costs of stay at the Intensity Care Unit (ICU) and Standard Ward 
Care (SWC). Three different sizes of Tachosil® were used; 3 cm x 2.5 cm (NOK 514), 4.8 
cm x 4.8 cm (NOK 1,440) and 9.5 cm x 4.8 cm (NOK 2,620). Two different sizes of Neuro-
Patch® were used; 1.5 cm x 3 cm (NOK 369) and 4 cm x 5 cm (NOK 742). The mean 
sealing product cost used during an operation in the Neuro-Patch® group and in the 
Tachosil® group was calculated. 
The cost of one day at the ICU in the Neurosurgical department at Ullevål University 
Hospital was NOK 27,000 and the cost of one day of SWC was NOK 4,800. The mean cost 
of a patient from the Neuro-Patch® group staying at the ICU (1.93*27,000) and the mean 
cost of SWC (7.93*4,800) were calculated, and the same calculations were made for the 
Tachosil® group (1.42*27,000 and 5.92*4,800).  
The costs in the combination group and in the Duragen® group were not calculated. Due to 
limitation of available data, the part of the analysis which included costs was inadequate.  
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Table 4: Unit costs of cost items included in the study 
Cost variable Description Cost (NOK) Source 
Tachosil®1 3 cm x 2.5 cm 514 Manufacturer (Nycomed) 
Tachosil®2 4.8 cm x 4.8 cm 1,440 Manufacturer (Nycomed) 
Tachosil®3 9.5 cm x 4.8 cm 2,620 Manufacturer (Nycomed) 
Neuro-Patch®1 1.5 cm x 3 cm 369 Manufacturer (B. Braun) 
Neuro-Patch®2 4 cm x 5 cm 742 Manufacturer (B. Braun) 
ICU stay One day stay at the Intensity 
Care Unit 
27,000 The administration of the Neurosurgical 
department at Ullevål  
SWC stay One day of Standard Ward 
Care 
4,800 The administration of the Neurosurgical 
department at Ullevål 
 
7.4 Statistical tests 
The patients were divided into four groups according to which sealing technique that were 
used during the operation. Differences between the groups in terms of patient characteristics, 
complications and number of reoperations were tested by a Chi-Square test, and were 
considered statistically significant when the p-value were <0.05. The differences in resource 
use were tested by a t-test, and were considered statistically significant when the p-value 
were <0.05. 
Logistic regression analyses were performed to test the relationship between each 
complication (CSF-leak, meningitis, diabetes insipidus, bleeding and death) and various 
independent variables (age, sex, elective surgery, endoscope, size, vision affection, hormonal 
activity and Tachosil). The variables were coded as described in Appendix 1.  
In binary logistic regression, we assume that the probability of the outcome (p) has the 
following functional form: 
Log (p/1-p) = β0 +β1X1 
Where β0 denotes the constant of the regression equation while β1 is a vector of regression 
coefficients and X1 is a vector of covariates. The natural logarithm is: 
e = 2.71828 
All statistical tests were performed in the software program SPSS. 
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8. Results 
8.1 Patient characteristics 
The age of the 81 patients varied from 16 to 83 with a mean of 58 and a median of 63 (Table 
5). There was a reasonably equal distribution of males and females in the patient group, 46% 
versus 54%. A macroadenoma was diagnosed in 86% of the cases, a hormonal active 
adenoma in 44% of the cases, and vision affection was detected in 57% of the patients. 
Endoscopic technique was used in 58% of the operations and 93% of the operations were 
elective. Many of the patients had various secondary diagnoses (Appendix 2), frequently 
more than one; 26% of the patients had no secondary diagnoses, 26% had one, 27% had two, 
11% had three, and 9.9% of the patients had four or more secondary diagnoses.  
Four different sealing techniques were used at Ullevål University Hospital during the years 
of 2006-2008. Neuro-Patch® was used on all patients in 2006 and on most of the patients in 
2007. In total, 60 patients received treatment with Neuro-Patch®, 13 patients received 
Tachosil®, 8 patients received a combination of Neuro-Patch® and Tachosil®, and one 
patient received treatment with a third sealing product called Duragen®. The mean age was 
49 in the Tachosil® group, 59 in the Neuro-Patch® group and 59 in the combination group. 
The proportion female was 31% in the Tachosil® group, 57% in the Neuro-Patch® group 
and 75% in the combination group. Patients with macroadenoma were reasonably equally 
distributed between the groups, as well as the number of patients undergone elective surgery. 
There were fewer patients experiencing vision affection (39% versus 62% and 50%) and 
fewer patients (31% versus 47% and 50%) who had a hormonal active tumour in the 
Tachosil® group than in the other two groups. Endoscopic technique was implemented at 
Ullevål first in the late part of 2006, and therefore only 43% of the operations in the Neuro-
Patch® group were performed with that technique, whilst all patients in the other groups 
were operated with endoscopic technique. Overall, there were fewer patients with secondary 
diagnoses in the Tachosil® group. None of the differences in patient characteristics between 
the groups were statistically significant.  
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Table 5: Characteristics of the 81 patients according to sealing technique 
 Neuro-Patch® 
(N = 60) 
Tachosil® 
(N = 13) 
Neuro-Patch®/Tachosil® 
(N = 8) 
P-value 
 
All 
(N = 81) 
Mean Age 
Median Age 
Age range 
59.4 
60.0 
58 (25 - 83) 
48.7 
48.0 
63 (16 - 
79) 
59.3 
62.5 
34 (45 - 79) 
 57.7 
62.5 
67 (16 - 83)  
Female 56.7 %  30.8 % 75.0 % 0.110 54.3 % 
Size of tumor > 10 
mm 
85.0 % 92.3 % 87.5 % 0.781 86.4 % 
Vision –affection 61.7 % 38.5 % 50.0 % 0.285 56.8 % 
Hormonal active 46.7 % 30.8 % 50.0 % 0.548 44.4 % 
Elective surgery 91.7 % 100.0 % 87.5 % 0.492 92.6 % 
Endoscope 43.3 % 100.0 % 100.0 % 0.000 58.0 % 
No secondary 
diagnoses 
23.3 % 38.5 % 25.0 % 25.9 % 
One secondary 
diagnosis 
23.3 % 38.5 % 25.0 % 25.9 % 
Two secondary 
diagnoses 
33.3 % 7.7 % 12.5 % 27.2 % 
Three secondary 
diagnoses 
10.0 % 15.4 % 12.5 % 11.1 % 
Four or more 
secondary 
diagnoses 
10.0 % 0.0 % 25.0 % 
 
 
 
 
0.376 
9.9 % 
* When performing the Chi-Square test, the Duragen® group was excluded. 
8.2 Health outcomes 
The overall complication rate was 26%, with variations between the different types (Table 
6). CSF-leak was present in 8.6% of the cases, meningitis in 6.2%, diabetes insipidus in 
15%, bleeding in 8.6 %, other complications in 4.9%, and death within one month in 2.5% of 
the cases. Reoperations were performed when total tumour removal was not achieved or for 
other reasons. A patient was reoperated once in 11% of the cases, twice in 6.2%, and a third 
time in 1.2% of the cases.  
The patients in the Neuro-Patch® group experienced a complication rate of 25%, which is 
similar to the patients in the Tachosil® group who had a complication rate of 23%. The 
patients receiving a combination of Neuro-Patch® and Tachosil® had a higher complication 
rate (38%). A CSF-leakage was detected in 8.3% of the cases in the Neuro-Patch® group, 
7.7% in the Tachosil® group, and in 13% in the combination group. Meningitis was the 
complication with the lowest incidence rate in both the Neuro-Patch® group (5%) and the 
Tachosil® group (0%), but had fairly high incidence rate in the combination group (25%). 
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Diabetes insipidus had the highest incidence rate in all three groups; 10% in the Neuro-
Patch® group, 23% in the Tachosil® group, and 38% in the combination group. Bleeding 
was considered as a complication in 8.3% of the patients in the Neuro-Patch® group, 7.7% 
in the Tachosil® group, and in 13% of the patients in the combination group. Other 
complications such as pneumonia was detected in 5% of the cases in the Neuro-Patch® 
group, 0% in the Tachosil® group, and in 13% of the cases in the combination group. In 
some cases, more than one complication was observed. Two patients died within one month 
after the patients was discharged from the hospital; one in the Neuro-Patch® group and one 
in the Tachosil® group. The differences between the groups in terms of complication rates 
were not statistically significant. 
In the Tachosil® group, 7.7% of the patients were reoperated once, whilst no patients were 
operated a second or third time. 12% of the patients in the Neuro-Patch® group had one 
reoperation, 6.7% had a second reoperation, and no patients had a third operation. All the 
patients in the combination group that went through a first reoperation (13%) also went 
through a second and a third, hence only patients from the combination group were 
reoperated a third time. The differences between the groups in terms of a third reoperation 
was statistically significant (p = 0.010) 
Table 6: Complications and reoperations according to type of sealing technique  
 Neuro-Patch® 
(N = 60) 
Tachosil® 
(N = 13) 
Neuro-Patch®/Tachosil® 
(N = 8) 
P-value All 
(N = 81) 
Any Complication 25.0 % 23.1 % 37.5 % 0.726 25.9 % 
CSF leak 8.3 % 7.7 % 12.5 % 0.917 8.6 % 
Meningitis 5.0 % 0.0 % 25.0 % 0.053 6.2 % 
Diabetes insipidus 10.0 % 23.1 % 37.5 % 0.079 14.8 % 
Bleeding 8.3 % 7.7 % 12.5 % 0.917 8.6 % 
Other complications 5.0 % 0.0 % 12.5 % 0.438 4.9 % 
Death 1.7 % 7.7 % 0.0 % 0.399 2.5 % 
One reoperation  11.7 % 7.7 % 12.5 % 0.910 11.1 % 
Two reoperations  6.7 % 0.0 % 12.5 % 0.488 6.2 % 
Three reoperations  0.0 % 0.0 % 12.5 % 0.010 1.2 % 
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8.3 Lengths of stay and costs 
The mean ICU LOS in the Tachosil® group was 1.42 days and SWC LOS was 5.92 days, 
while the numbers were 1.93 and 7.93 in the Neuro-Patch® group (Table 7). There was no 
statistically significant difference between the sealing groups in terms of ICU LOS or SWC 
LOS. The mean cost of the sealing product was NOK 394 in the Neuro-Patch® group and 
NOK 1,261 in the Tachosil® group. The difference between the sealing groups according to 
mean costs of the sealing products used was statistically significant (p<0.001).The mean 
ICU cost of a patient in the Neuro-Patch® group was NOK 52,200 and NOK 38,250 in the 
Tachosil® group (p=0.265). The mean SWC cost in the Neuro-Patch® group was NOK 
38,080 and NOK 28,400 in the Tachosil® group (p=0.856).  
Table 7: Mean resource use according to type of sealing technique* 
 Neuro-Patch® Tachosil® P-value 
ICU LOS ** 1.93 days 1.42 days*** 0.265 
SWC LOS** 7.93 days 5.92 days*** 0.856 
    
Cost Sealing product 394 1,261 0.000 
Cost ICU  52,200 38,250*** 0.265 
Cost Standard Ward Care  38,080 28,400*** 0.856 
* The resource use comparisons were only performed for the Neuro-Patch®- and Tachosil® groups because of 
few patients in the remaining two groups. 
** ICU LOS and SWC LOS represent data (the mean) from the first surgeries and in some cases also second 
and third surgeries. 
*** One patient in the Tachosil® group died during surgery; hence there is no data on ICU LOS or SWC LOS 
for that patient.  
8.4 Logistic regression 
The logistic regression equation for the occurrence of complications was expressed as: 
logit(p) = β0 +β1 * Age + β2 * Sex + β3 * ElSurg + β4 * Endoscope + β5 * Size + β6 * 
VisAff + β7 * HormAct + β8 * Tachosil®  
Where p is the probability of a complication. 
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In the logistic regression analysis of the odds for diabetes insipidus (Table 8), the odds ratio 
was 0.936 for age (95% CI 0.889-0.985, p=0.012) while the other covariates were not 
significant. In none of the other regression analyses of the other complications, there were 
any significant covariates (see Appendix 3). 
Table 8: Logistic regression on diabetes insipidus and explanatory variables 
95.0 % C.I  Variable P-value Odds ratio 
Lower Upper 
Age (years) 0.012 0.936 0.889 0.985 
Sex (0 = male 1 = female) 0.784 1.231 0.278 5.462 
Elective surgery (0 = no 1 = yes) 0.576 2.034 0.169 24.489 
Endoscope (0 = no 1 = yes) 0.187 2.989 0.587 15.217 
Size (0 = micro 1 = macro) 0.384 3.437 0.213 55.399 
Vision affection (0 = no 1 = yes) 0.330 2.306 0.429 12.382 
Hormonal active (0 = no 1 = yes) 0.654 1.418 0.308 6.538 
Tachosil® (0 = no 1 = yes) 0.738 0.705 0.091 5.464 
Constant 0.578 0.260 
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9. Discussion 
The results of the study indicate that there is no difference in the risk of complications 
between the Neuro-Patch® group and the Tachosil® group, nor is there any cost difference 
except for the sealing products itself. However, there are several weaknesses of the study 
that need to be considered. 
9.1 Weaknesses 
9.1.1 Sample size and distribution 
The sample was limited in the number and unbalanced in that the number of Neuro-Patch® 
patients was much greater than the number of Tachosil® patients, and also there was a group 
of patients receiving a combination of Tachosil® and Neuro-Patch® in addition to a fourth 
group where one patient received Duragen®. Hence, the patients were not equally 
distributed between the groups. 
Another limitation of the study is that the Neurosurgical department during the study period 
changed sealing techniques as well as operation technique, and it is difficult to disentangle 
the consequences of the two changes.  
9.1.2 Fatality rate  
The follow-up time of counting the number of deaths was one month after the patient was 
discharged from the hospital in order to have the same follow up period for all patients. 
Consequently, several deaths that occurred later are not included in the study. Ideally, a Cox 
regression analysis could have solved the problem. 
Also, there was no information in the data set on the causes of death. Hence, there is a 
possibility that causes of deaths had nothing to do with complications followed from the 
operations.  
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9.1.3 Omitted variables 
To evaluate the effectiveness of Tachosil®, information on the length of the operations 
would have been preferred. Unfortunately, this information was available in less than 60% 
of the Neuro-Patch® patients and less than 85% of the Tachosil® patients.  
In terms of reoperations, the registration on ICU LOS and SWC LOS was not consistent. If a 
patient was discharged from the hospital, and then hospitalized again for a reoperation, no 
information on the length of stay was registered. However, if the patient was reoperated 
before being discharged, the total length of stay was captured. Therefore, the calculated 
mean of ICU LOS and SWC LOS was not accurate.  
9.1.4 Costs 
Due to the inaccurate data on ICU LOS and SWC LOS, the cost of hospitalization would 
also be inaccurate. More importantly, many cost items that should have been included in the 
study (to provide a true picture of the costs involved) were not identified (costs of GP visits, 
surgery, other treatment costs, personal costs, and more). The study results should therefore 
not be used to make inferences about differences in total costs across the sealing techniques. 
9.2 Strengths  
Since the sample used for this study were identified in operation protocols, there is reason to 
believe that all patients that underwent TSS for removing pituitary tumours at Ullevål 
University Hospital in the years 2006-2008 were identified.  
Several characteristics of the patients (age, sex, size of tumour and more) were captured, as 
well as the complication rates and sealing technique that was used during the operations.  
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9.3 Interpretation of the results 
The stated hypotheses have been tested by statistical tests such as logistic regressions, Chi-
Square tests and t-tests. None of the alternative hypotheses were confirmed and the null 
hypotheses can not be rejected. Although it would be tempting to discuss indications of 
possible differences in terms of complications and length of stay between the sealing groups, 
I will not do that.   
9.4 Findings of other studies 
The only comparable study, is the study by Tamašauskas et al. Tachosil® was used as a 
sealing agent (in combination with Surgicel®) after removing pituitary tumours with TSS, 
and when intraoperative CSF-leaks were present. The postoperative complication rate for the 
Tachosil® group was 14%, compared to a total complication rate of 23% in this study. The 
registration of complications was not identical, however. One problem when comparing the 
studies is that Tachosil® in the Tamašauskas study, only was used when intraoperative CSF-
leaks were present, while in this study it was used even when the complication was not 
present. Also, CSF-leaks were not classified as intra- or postoperative in the data set used for 
this study, as in the Tamašauskas study. In fact, if including intraoperative CSF-leaks as a 
complication, the complication rate would have been much higher than 14%. Tamašauskas 
concluded that Tachosil® was the more effective sealing agent compare to the other method 
used. No such conclusions can be made from this study.  
9.5 Implication and conclusion 
The results of this study do not confirm any of the hypotheses, and do not provide any 
evidence that Tachosil® is superior in terms of complications or length of stay.  
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10. Appendix 
Appendix 1: List of variables 
Variables extracted from 82 patient records at Ullevål University Hospital 
Variable name Explanation Type  Coding 
RegNr Registration number Numerical 200xxx 
Age Age of the patient Numerical Years 
Sex Sex of the patient Categorical 1 = Female 
0 = Male        
MainDiag Main diagnose Categorical ICD-10 coding 
SecondDiag Secondary diagnoses Categorical ICD-10 coding 
Size Size of the tumour Categorical 1 = Macro 
0 = Micro 
VisAff Vision affection Categorical 1 = Yes 
0 = No 
HormAct Hormonal active tumour  Categorical 1 = Yes 
0 = No 
ElSurg Elective surgery Categorical 1 = Yes 
0 = No 
SurgCode Surgery code Categorical Operation code 
SurgTime Length of surgery in 
minutes 
Numerical Minutes 
ICULOS Total length of stay at the 
intensity care 
Numerical Days 
SWC LOS Total length of stay at the 
standard ward care unit 
Numerical Days 
TotalLOS Total length of stay at the 
hospital 
Numerical Days 
Endoscope Use of endoscope Categorical 1 = Yes 
0 = No 
SealingTech Sealing technique Categorical 1 = Tachosil® 
0 = Neuro-Patch® 
2 = Tach/Neuro 
3 = Duragen® 
DRG DRG code Categorical DRG coding 
ProdCm Cm of the sealing 
product  
Categorical Tachosil®;  
1 = 9.5cm x 4.8 cm 
2 = 3.0cm x 2.5cm 
3 = 4.8cm x 4.8cm  
Neuro-Patch®;  
1 = 1.5cm x 3cm 
2 = 4cm x 5cm 
Complications Complications  Categorical 1 = Yes 
0 = No 
CSFLeak Cerebrospinal fluid 
leakage 
Categorical 1 = Yes 
0 = No 
Bleeding Bleeding Categorical 1 = Yes 
0 = No 
Diabetes Diabetes insipidus Categorical 1 = Yes 
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0 = No 
Meningitis Meningitis Categorical 1 = Yes 
0 = No 
OtherCompl Other complications Categorical 1 = Yes 
0 = No 
Reoper Reoperation Categorical 1 = Yes 
0 = No 
Death Death registered within a 
timeframe of one month 
Categorical 1 = Yes 
0 = No 
Appendix 2: ICD-10 codes 
The ICD-10 codes are classified into sub-categories14. The table shows the prevalence of 
the present sub-categories in the four sealing groups 
 Neuro-Patch® 
(N = 60) 
Tachosil® 
(N = 13) 
Neuro-
Patch®/Tachosil® 
(N = 8) 
Duragen® 
(N = 1) 
Neoplasm 100.0 % 100.0 % 100.0 % 100.0 % 
Endocrine, nutritional and 
metabolic diseases 
41.7 % 23.1 % 62.5 % 0.0 % 
Diseases of the circulatory system 36.7 % 23.1 % 37.5 % 0.0 % 
Injury, poisoning and certain 
other consequences of external 
causes 
8.3 % 7.7 % 12.5 % 0.0 % 
Diseases of the ear and mastoid 
process 
1.7 % 0.0 % 0.0 % 0.0 % 
Diseases of eye and adnexa 1.7 %  0.0 % 0.0 % 0.0 % 
Diseases of the nervous system 10.0 % 15.4 % 25.0 % 100.0 % 
Diseases of the respiratory system 11.7 % 0.0 % 0.0 % 0.0 % 
Diseases of the musculoskeletal 
system and connective tissue 
11.7 % 0.0 % 12.5 % 100.0 % 
Diseases of the digestive system 3.3 % 0.0 % 12.5 % 0.0 % 
Congenital malformations, 
deformations and chromosomal 
abnormalities 
1.7 % 0.0 % 0.0 % 0.0 % 
Certain infectious and parasitic 
diseases 
1.7 % 0.0 % 0.0 % 0.0 % 
Factors influencing health status 
and contact with health services 
0.0 % 15.4 % 0.0 % 0.0 % 
Symptoms, signs and abnormal 
clinical and laboratory findings, 
not elsewhere classified 
0.0 % 7.7 % 0.0 % 0.0 % 
Diseases of the genitourinary 
system 
1.7 % 0.0 % 0.0 % 100.0 % 
Mental and behavioural disorders 1.7 % 0.0 % 12.5 % 0.0 % 
                                              
14 International Statistical Classification of Diseases and Related Health Problems. 10th Revision. Version for 2007. 
Extracted from WHO. 
 54 
Appendix 3: Logistic regression 
 Logistic regression on CSF-leak and explanatory variables 
95.0 % C.I  Variable P-value Odds ratio 
Lower Upper 
Age  0.537 0.976 0.905 1.054 
Sex 0.392 2.222 0.358 13.812 
Elective surgery 0.999 2.892E8 0.000  
Endoscope 0.276 3.116 0.404 24.061 
Size 1.000 3.948 0.000  
Vision affection 0.153 0.277 0.048 1.607 
Hormonal active 0.998 0.000 0.000  
Tachosil 0.270 0.177 0.008 3.828 
Constant 0.999 0.000 
 
Logistic regression on bleeding and explanatory variables 
95.0 % C.I  Variable P-value Odds ratio 
Lower Upper 
Age  0.167 0.956 0.896 1.019 
Sex 0.054 0.082 0.006 1.049 
Elective surgery 0.999 1.022E8 0.000  
Endoscope 0.182 0.231 0.027 1.988 
Size 0.999 1.106E8 0.000  
Vision affection 0.556 0.520 0.059 4.581 
Hormonal active 0.491 0.500 0.069 3.595 
Tachosil 0.485 0.334 0.015 7.243 
Constant 0.999 0.000 
 
Logistic regression on meningitis and explanatory variables 
95.0 % C.I  Variable P-value Odds ratio 
Lower Upper 
Age  0.050 0.905 0.818 1.000 
Sex 0.269 0.208 0.013 3.358 
Elective surgery 0.999 4.924E8 0.000  
Endoscope 0.997 4.076E8 0.000  
Size 0.576 0.281 0.003 24.073 
Vision affection 0.811 0.747 0.068 8.157 
Hormonal active 0.149 0.071 0.002 2.578 
Tachosil 0.998 0.000 0.000  
Constant 0.998 0.000 
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Logistic regression on death and explanatory variables 
95.0 % C.I  Variable P-value Odds ratio 
Lower Upper 
Age  0.959 1.003 0.880 1.144 
Sex 0.996 0.000 0.000  
Elective surgery 0.999 0.000 0.000  
Endoscope 0.996 0.000 0.000  
Size 1.000 1.007 0.003  
Vision affection 0.997 0.000 0.000  
Hormonal active 0.998 0.000 0.002  
Tachosil 0.997 4.910E7 0.000  
Constant 0.999 4.094E13 
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